Global NF kB Inhibitors Pipeline Insights 2019

"NF-κB Inhibitors- Pipeline Insights, 2019" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across NF-κB Inhibitors. A detailed picture of the pipeline landscape is provided with summation of data from multiple sources with complete analysis by development stage, mechanism of action, route of administration and molecule type. This report provides detailed analysis of 12+ active products with more than 10 companies involved. Some of the key players include AMG0101 of AnGes MG and Bardoxolone methyl of Reata Pharmaceuticals, and BIIB098 of Alkermes/Biogen.

Products covered by Phase
• Phase III, Phase II, Phase I
• Pre-clinical
• Inactive (Dormant and Discontinued)

Overview of pipeline development activities for NF-κB Inhibitors
Pipeline analysis of therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and pre-clinical results, designations, collaborations & licensing deals, grants, technology and patent details.

Therapeutic segmentation of products for NF-κB Inhibitors
The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this mechanism.

Methodology

Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts.
Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Scope of the report

• Provides an overview of therapeutic pipeline activity for NF-κB Inhibitors across the complete product development cycle including all clinical and non-clinical stages
• It comprises of detailed profiles of NF-κB Inhibitors therapeutic products with key coverage of developmental activities including licensing & collaboration deals, patents issued, designations, technologies and chemical information
• Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration
• Coverage of dormant and discontinued pipeline projects across NF-κB Inhibitors

Reasons to Buy

• Establish a comprehensive understanding of the current pipeline scenario across NF-κB Inhibitors to formulate effective R&D strategies
• Assess challenges and opportunities that influence NF-κB Inhibitors R&D
• Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
• Identify the relationship between the products and use it for target finding, drug repurposing, and precision medicine
• Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for NF-κB Inhibitors to enhance and expand business potential and scope
• Our extensive domain knowledge on therapy areas support the client in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive and discontinued drugs

Executive Summary
Overview
Introduction
Structure
Mechanism of Action
Inducers
Repressors
Clinical Significance
NF-κB Inhibitors
Pipeline Therapeutics (Active Products)
Pipeline Therapeutics (Inactive Products)
Comparative Analysis
Late Stage Products (Phase III)
Comparative Analysis
AMG0101: AnGes MG
Product Description
Research and Development
Product Development Activities
The list continues….
Mid Stage Products (Phase II)
Comparative Analysis
CPI-0610: CONSTELLATION
Product Description
Research and Development
Product Development Activities
The list continues….
Early Stage Products (Phase I)
Comparative Analysis
Pre-clinical Stage Products
Comparative Analysis
Therapeutic Assessment: Active Products
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Inactive Products (Dormant & Discontinued Products)
Comparative Analysis
Appendix

List of Tables

Table 1: Total Products for NF κB Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical Stage Products
Table 6: Assessment by Stage and Product Type
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Inactive Products

List of Figures

Figure 1: Total Products for NF κB INHIBITORS
Figure 2: Late Stage Products (Phase III)
Figure 3: Mid Stage Products (Phase II)
Figure 4: Early Stage Products (Phase I)
Figure 5: Pre-clinical Stage Products
Figure 6: Assessment by Stage and Product Type
Figure 7: Assessment by Route of Administration
Figure 8: Assessment by Stage and Route of Administration
Figure 9: Assessment by Molecule Type
Figure 10: Assessment by Stage and Molecule Type
Figure 11: Inactive Products